Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY)

BACKGROUND: There are currently no treatments for empathy deficits in neuropsychiatric disorders. Acute administration of the hormone oxytocin has been associated with symptomatic improvements across animal models and several neuropsychiatric disorders, but results of the majority of oxytocin random...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Alzheimers Res Ther
Autors principals: Finger, Elizabeth, Berry, Scott, Cummings, Jeffrey, Coleman, Kristy, Hsiung, Robin, Feldman, Howard H., Boxer, Adam
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6161323/
https://ncbi.nlm.nih.gov/pubmed/30261917
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-018-0427-2
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars